- For Dose Confirmation Phase NSCLC Arms: Have newly diagnosed histologically or cytologically-confirmed stage IIIB/stage IV NSCLC and must be negative for epidermal growth factor receptor (EGFR) mutation and negative for anaplastic lymphoma kinase (ALK) translocation. Participant must not have received prior systemic treatment for advanced NSCLC or must have received previous neoadjuvant and adjuvant chemotherapies ≥6 months before dosing of study drug if prior systemic treatment was given for early stage disease